肿瘤抗血管靶向治疗相关标志物研究进展及其在骨与软组织肉瘤中的潜在应用  

Single nucleotide polymorphisms(SNPs)associated with antiangiogenesis in tumor targeted treatment and potential application in osteosarcoma and soft tissue sarcoma

作　　者：朱天翼 施薇文 王婧 丽娜·别克木合买提 鲍其远 沈宇辉[1,2] ZHU Tian-yi;SHI Wei-wen;WANG Jing;LINA Biekemuhemaiti;BAO Qi-yuan;SHEN Yu-hui(Department of Orthopaedics,Ruijin Hospital,Shanghai Jiaotong University School of Medicine,Shanghai,200025,China)

机构地区：[1]上海交通大学医学院附属瑞金医院骨科,200025 [2]上海交通大学医学院,200025

出　　处：《中国骨与关节杂志》2021年第5期348-358,共11页Chinese Journal of Bone and Joint

摘　　要：骨与软组织肉瘤皆为恶性程度高、预后差的恶性肿瘤,起源于间叶组织,主要累及骨及骨周围的筋膜、肌肉、脂肪和脉管等。骨肉瘤好发于20岁以下的儿童和青少年以及65岁以上的老人[1],易转移至肺(HR=2.34;95%CI 1.95~2.81),即便在接受规范的手术和药物治疗的40岁以下病患中,5年无进展生存率仍仅为54%(95%CI52%~56%)[2]。值得注意的是,骨肉瘤仅占新发肉瘤的15%,其余85%新发肉瘤来源于软组织[3]。Osteosarcoma and soft tissue sarcoma are both rare malignant tumors with poor prognosis,which cause great losses to patients and their families.Angiogenesis is one of the most important processes in tumor growth and metastasis.It has been reported that vascular endothelial growth factors (VEGFs) and their receptors VEGFRs play an important role in the pathological angiogenesis in the process of osteosarcoma and soft tissue sarcoma metastasis,suggesting the antiangiogenesis targeted therapy (ATT) based on VEGF / VEGFR pathway is promising in clinic.Small-molecule targeted agents,represented by receptor tyrosine kinase inhibitors (VEGFR-TKIs),have recently showed some anti-tumor efficacy in advanced osteosarcoma and soft tissue sarcoma in preliminary clinical trials after the early endeavor of bevacizumab.However,the efficacy of VEGFR-TKIs varies among individuals so that it is urgent to find reliable and sensitive biomarkers to predict the clinical efficacy of ATT.Researchers have tried to utilize circulating markers,adverse effects,imaging and pharmacogenomic characteristics as predictive biomarkers and have succeeded in certain types of cancer.Among all types of biomarkers,single nucleotide polymorphisms (SNPs)are promising in numbers of prospective clinical trials.This review summarized the current progress of ATT and related biomarkers to provide references for further exploration of accurate and individualized therapy in the treatment of osteosarcoma and soft tissue sarcoma.

关 键 词：抗血管 生物标志物 骨肉瘤 单核苷酸多态性 软组织肉瘤 综述 

分 类 号：R738.1[医药卫生—肿瘤] R738.6[医药卫生—临床医学]